Direxion Daily Healthcare Bull 3X ETF (CURE)

The Direxion Daily Healthcare Bull 3X ETF (ticker: CURE) is a leveraged exchange-traded fund that amplifies single-day price movements in the U.S. healthcare sector threefold. It is not designed to hold for more than one trading session at a time, and holding it longer than that exposes investors to the mathematical drag of daily rebalancing — a phenomenon called volatility decay.

The healthcare sector and why it matters

The U.S. healthcare sector spans drug manufacturers, medical device makers, biotechnology firms, healthcare insurance companies, and clinical lab operators. It is one of the largest and most defensive sectors in the stock market, meaning that healthcare stocks tend to hold up relatively well even when the broader economy stumbles. Patients do not stop taking medications or seeking care during downturns, so health-care revenue remains relatively stable. This defensive profile—along with the sector’s exposure to aging demographics, obesity, diabetes, and chronic illness—has made healthcare a perennial part of a diversified portfolio.

CURE is a bet that the healthcare sector will rise sharply in a single day. For investors convinced that a sector rally is imminent, 3x leverage can turn a modest 1% daily gain in healthcare into a 3% gain in the fund. The inverse holds: a 1% daily decline becomes a 3% loss. This amplification is why CURE trades primarily among professional traders and sophisticated options specialists managing specific intraday positions.

How CURE achieves 3x leverage

The fund does not own 3 dollars’ worth of healthcare stocks for every 1 dollar invested in the ETF. Instead, Direxion uses a mix of financial derivatives—primarily equity index swaps and futures contracts—to create a leveraged position. Swaps are agreements to exchange the performance of the healthcare index for a leveraged return; futures allow the fund to control a large notional position with a small amount of capital. These instruments let Direxion amplify the fund’s daily movement without holding triple the stock—a mathematical trick that comes with its own costs and constraints.

Every single trading day, CURE rebalances to maintain exactly 3x leverage. If the healthcare sector rises sharply, the fund’s gain is larger than 3x that day’s move (because the fund’s leverage ratio compounds). The fund then sells some of its derivatives position and raises cash to bring leverage back to exactly 3x by the end of the trading day. This daily reset is what makes CURE a single-day bet rather than a multi-day one. Over a week or month, the cumulative effect of daily rebalancing, slippage, and trading costs erodes the fund’s value in a way that has little to do with the sector’s actual performance.

The volatility-decay trap

Here is the central mathematical fact about CURE: if the healthcare sector is flat over two days, the fund will not be flat. It will be down.

Suppose healthcare rises 2% on Day 1 and falls 2% on Day 2, a round trip. The sector returns to its starting point. CURE rises 6% on Day 1 (3 times 2%), then is rebalanced and falls 6% on Day 2. The sector returned 0%; CURE returned −0.36% (a 6% gain on the leverage amount, then a 6% loss on a larger balance). This is volatility decay: when an underlying asset swings around without trending, daily rebalancing of a leveraged fund drags its performance down.

The decay accelerates with volatility. In periods of wild sector swings, CURE loses value even if the sector ends the month where it started. This is why the fund’s prospectus, fact sheet, and Direxion’s own marketing material emphasize that CURE is not suitable for buy-and-hold investors. Trading it as a multi-week or multi-month holding is not using the tool as intended; it is accepting a hidden tax on volatility that has nothing to do with the fund’s stated objective.

Why someone would trade CURE

The audience is narrow: portfolio managers and traders who operate within a single trading session and want to amplify a directional bet in healthcare. A quantitative hedge fund might use CURE to gain quick exposure during a healthcare-friendly news cycle, then unwind the position before the market close. A day trader convinced that healthcare will pop 0.5% might buy CURE to capture a 1.5% move instead. An options trader might pair CURE with outright stock positions to dynamically adjust sector exposure in real time.

For any of these uses, CURE’s liquidity and tight intraday tracking of its leverage mandate make it a reasonable tool. The bid-ask spread (the cost of entry and exit) is wider than ordinary equity ETFs—a typical leveraged fund might spread 0.05% to 0.20% wide—but for a one-day position, that cost is absorbed in the expected return.

The risks and hidden costs

The first risk is the one above: volatility decay. Holding CURE beyond its intended single-trading-day horizon is mathematically doomed in any sideways or choppy market. That is not a failure of the fund; it is a failure of the strategy.

The second is fees. CURE’s expense ratio of roughly 0.95% per year is extraordinarily high compared to a plain healthcare ETF, which might charge 0.10% to 0.40%. That fee alone is a powerful argument against holding the fund for weeks or months. But the true all-in cost is higher: the daily rebalancing generates trading costs (commissions, bid-ask slippage, market impact) that show up in the fund’s daily price but not in the stated expense ratio. Over a year, the total drag can be several percentage points.

The third is the leverage itself. If the healthcare sector plunges 10% in a single day—a tail-risk scenario, but not impossible in a major crisis—CURE would fall 30%. A 30% loss in a single day would wipe out three years of calm returns for a buy-and-hold investor. That is the price of the amplification: catastrophic downside on bad days.

The fourth is slippage in rebalancing. When CURE rebalances daily, it must trade in and out of derivative positions, moving the market slightly. In illiquid periods or large market dislocations, that rebalancing can cause the fund to lag its stated leverage target, a phenomenon called tracking error. During a crisis, when you most want the leverage to work, it may fail partially.

Who CURE is for and who it is not for

CURE is for a trader with a specific, intraday directional thesis about healthcare and the sophistication to understand leverage, daily rebalancing, and volatility decay. It is not for a retirement account, not for a long-term portfolio, and not for anyone who does not understand the math of compounding losses in a down market.

To research CURE further, read the prospectus and fact sheet on Direxion’s website, which spell out the daily reset mechanism and the volatility-decay risk plainly. The SEC’s Office of Investor Education and Advocacy also publishes materials on leveraged ETF risks. Search the fund’s actual holdings and daily returns over a multiweek period to develop an intuition for how much slippage and decay occur outside of single-trading-day swings.